Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia (GEXANT)
Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia: Evidence From Pharmacogenetics in the Light of Personalized Medicine
Sponsor: Centro de Investigación Biomédica en Red de Salud Mental
Listed as NCT02205437, this observational or N/A phase trial focuses on Schizophrenia and remains ongoing. Sponsored by Centro de Investigación Biomédica en Red de Salud Mental, it has been updated 15 times since 2015, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Oct 2021 — Dec 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
▶ Show 10 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Feb 2020 — Nov 2020 [monthly]
Recruiting
-
Mar 2019 — Feb 2020 [monthly]
Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Apr 2017 — Aug 2017 [monthly]
Recruiting NA
-
Feb 2017 — Apr 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centro de Investigación Biomédica en Red de Salud Mental
- Fundación Marques de Valdecilla
- Instituto de Investigación Marqués de Valdecilla
For direct contact, visit the study record on ClinicalTrials.gov .